Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3-4/2013

Open Access 01-12-2013

The detection and implication of genome instability in cancer

Authors: Larissa Pikor, Kelsie Thu, Emily Vucic, Wan Lam

Published in: Cancer and Metastasis Reviews | Issue 3-4/2013

Login to get access

Abstract

Genomic instability is a hallmark of cancer that leads to an increase in genetic alterations, thus enabling the acquisition of additional capabilities required for tumorigenesis and progression. Substantial heterogeneity in the amount and type of instability (nucleotide, microsatellite, or chromosomal) exists both within and between cancer types, with epithelial tumors typically displaying a greater degree of instability than hematological cancers. While high-throughput sequencing studies offer a comprehensive record of the genetic alterations within a tumor, detecting the rate of instability or cell-to-cell viability using this and most other available methods remains a challenge. Here, we discuss the different levels of genomic instability occurring in human cancers and touch on the current methods and limitations of detecting instability. We have applied one such approach to the surveying of public tumor data to provide a cursory view of genome instability across numerous tumor types.
Literature
1.
Sieber, O. M., Heinimann, K., & Tomlinson, I. P. (2003). Genomic instability—the engine of tumorigenesis? Nature Reviews. Cancer, 3(9), 701–708.PubMedCrossRef
2.
3.
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1997). Genetic instability in colorectal cancers. Nature, 386(6625), 623–627.PubMedCrossRef
4.
Gorgoulis, V. G., Vassiliou, L. V., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., et al. (2005). Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature, 434(7035), 907–913.PubMedCrossRef
5.
Loeb, L. A. (2001). A mutator phenotype in cancer. Cancer Research, 61(8), 3230–3239.PubMed
6.
Bartkova, J., Horejsi, Z., Koed, K., Kramer, A., Tort, F., Zieger, K., et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature, 434(7035), 864–870.PubMedCrossRef
7.
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., et al. (2006). Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature, 444(7119), 633–637.PubMedCrossRef
8.
Halazonetis, T. D., Gorgoulis, V. G., & Bartek, J. (2008). An oncogene-induced DNA damage model for cancer development. Science, 319(5868), 1352–1355.PubMedCrossRef
9.
Janssen, A., van der Burg, M., Szuhai, K., Kops, G. J., & Medema, R. H. (2011). Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations. Science, 333(6051), 1895–1898.PubMedCrossRef
10.
Hackett, J. A., & Greider, C. W. (2002). Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene, 21(4), 619–626.PubMedCrossRef
11.
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., et al. (2011). Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell, 144(1), 27–40.PubMedCrossRef
12.
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998). Genetic instabilities in human cancers. Nature, 396(6712), 643–649.PubMedCrossRef
13.
Boland, C. R., & Goel, A. (2010). Microsatellite instability in colorectal cancer. Gastroenterology, 138(6), 2073–2087. e2073.PubMedCrossRef
14.
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., et al. (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26(35), 5705–5712.CrossRef
15.
Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N., & Szallasi, Z. (2006). A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nature Genetics, 38(9), 1043–1048.PubMedCrossRef
16.
Dworaczek, H., & Xiao, W. (2007). Xeroderma pigmentosum: a glimpse into nucleotide excision repair, genetic instability, and cancer. Critical Reviews in Oncogenesis, 13(2), 159–177.PubMedCrossRef
17.
Al-Tassan, N., Chmiel, N. H., Maynard, J., Fleming, N., Livingston, A. L., Williams, G. T., et al. (2002). Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nature Genetics, 30(2), 227–232.PubMedCrossRef
18.
Lee, H. C., Li, S. H., Lin, J. C., Wu, C. C., Yeh, D. C., & Wei, Y. H. (2004). Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutation Research, 547(1–2), 71–78.PubMedCrossRef
19.
Lee, H. C., Yin, P. H., Lin, J. C., Wu, C. C., Chen, C. Y., Wu, C. W., et al. (2005). Mitochondrial genome instability and mtDNA depletion in human cancers. Annals of the New York Academy of Sciences, 1042, 109–122.PubMedCrossRef
20.
Weissenbach, J., Gyapay, G., Dib, C., Vignal, A., Morissette, J., Millasseau, P., et al. (1992). A second-generation linkage map of the human genome. Nature, 359(6398), 794–801.PubMedCrossRef
21.
Thibodeau, S. N., Bren, G., & Schaid, D. (1993). Microsatellite instability in cancer of the proximal colon. Science, 260(5109), 816–819.PubMedCrossRef
22.
Ionov, Y., Peinado, M. A., Malkhosyan, S., Shibata, D., & Perucho, M. (1993). Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature, 363(6429), 558–561.PubMedCrossRef
23.
Risinger, J. I., Berchuck, A., Kohler, M. F., Watson, P., Lynch, H. T., & Boyd, J. (1993). Genetic instability of microsatellites in endometrial carcinoma. Cancer Research, 53(21), 5100–5103.PubMed
24.
Rhyu, M. G., Park, W. S., & Meltzer, S. J. (1994). Microsatellite instability occurs frequently in human gastric carcinoma. Oncogene, 9(1), 29–32.PubMed
25.
Halling, K. C., Harper, J., Moskaluk, C. A., Thibodeau, S. N., Petroni, G. R., Yustein, A. S., et al. (1999). Origin of microsatellite instability in gastric cancer. The American Journal of Pathology, 155(1), 205–211.PubMedCrossRef
26.
Kim, W. S., Park, C., Hong, S. K., Park, B. K., Kim, H. S., & Park, K. (2000). Microsatellite instability (MSI) in non-small cell lung cancer (NSCLC) is highly associated with transforming growth factor-beta type II receptor (TGF-beta RII) frameshift mutation. Anticancer Research, 20(3A), 1499–1502.PubMed
27.
Fishel, R., Lescoe, M. K., Rao, M. R., Copeland, N. G., Jenkins, N. A., Garber, J., et al. (1993). The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell, 75(5), 1027–1038.PubMedCrossRef
28.
Leach, F. S., Nicolaides, N. C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R., et al. (1993). Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell, 75(6), 1215–1225.PubMedCrossRef
29.
Bronner, C. E., Baker, S. M., Morrison, P. T., Warren, G., Smith, L. G., Lescoe, M. K., et al. (1994). Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature, 368(6468), 258–261.PubMedCrossRef
30.
Nicolaides, N. C., Papadopoulos, N., Liu, B., Wei, Y. F., Carter, K. C., Ruben, S. M., et al. (1994). Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature, 371(6492), 75–80.PubMedCrossRef
31.
Palombo, F., Gallinari, P., Iaccarino, I., Lettieri, T., Hughes, M., D'Arrigo, A., et al. (1995). GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science, 268(5219), 1912–1914.PubMedCrossRef
32.
Papadopoulos, N., Nicolaides, N. C., Wei, Y. F., Ruben, S. M., Carter, K. C., Rosen, C. A., et al. (1994). Mutation of a mutL homolog in hereditary colon cancer. Science, 263(5153), 1625–1629.PubMedCrossRef
33.
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J. P. (1999). CpG island methylator phenotype in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 96(15), 8681–8686.PubMedCrossRef
34.
Issa, J. P. (2004). CpG island methylator phenotype in cancer. Nature Reviews. Cancer, 4(12), 988–993.PubMedCrossRef
35.
Goel, A., Nagasaka, T., Arnold, C. N., Inoue, T., Hamilton, C., Niedzwiecki, D., et al. (2007). The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology, 132(1), 127–138.PubMedCrossRef
36.
Ogino, S., Nosho, K., Kirkner, G. J., Kawasaki, T., Meyerhardt, J. A., Loda, M., et al. (2009). CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut, 58(1), 90–96.PubMedCrossRef
37.
Vilar, E., & Gruber, S. B. (2010). Microsatellite instability in colorectal cancer—the stable evidence. Nature Reviews. Clinical Oncology, 7(3), 153–162.PubMedCrossRef
38.
Ward, R., Meagher, A., Tomlinson, I., O'Connor, T., Norrie, M., Wu, R., et al. (2001). Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut, 48(6), 821–829.PubMedCrossRef
39.
Gagos, S., & Irminger-Finger, I. (2005). Chromosome instability in neoplasia: chaotic roots to continuous growth. The International Journal of Biochemistry & Cell Biology, 37(5), 1014–1033.CrossRef
40.
Lee, A. J., Endesfelder, D., Rowan, A. J., Walther, A., Birkbak, N. J., Futreal, P. A., et al. (2011). Chromosomal instability confers intrinsic multidrug resistance. Cancer Research, 71(5), 1858–1870.PubMedCrossRef
41.
Walther, A., Houlston, R., & Tomlinson, I. (2008). Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut, 57(7), 941–950.PubMedCrossRef
42.
Solomon, D. A., Kim, T., Diaz-Martinez, L. A., Fair, J., Elkahloun, A. G., Harris, B. T., et al. (2011). Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science, 333(6045), 1039–1043.PubMedCrossRef
43.
O'Sullivan, R. J., & Karlseder, J. (2010). Telomeres: protecting chromosomes against genome instability. Nature Reviews Molecular Cell Biology, 11(3), 171–181.PubMedCrossRef
44.
Levitt, N. C., & Hickson, I. D. (2002). Caretaker tumour suppressor genes that defend genome integrity. Trends in Molecular Medicine, 8(4), 179–186.PubMedCrossRef
45.
Rotman, G., & Shiloh, Y. (1998). ATM: from gene to function. Human Molecular Genetics, 7(10), 1555–1563.PubMedCrossRef
46.
Cahill, D. P., Lengauer, C., Yu, J., Riggins, G. J., Willson, J. K., Markowitz, S. D., et al. (1998). Mutations of mitotic checkpoint genes in human cancers. Nature, 392(6673), 300–303.PubMedCrossRef
47.
Hanks, S., Coleman, K., Reid, S., Plaja, A., Firth, H., Fitzpatrick, D., et al. (2004). Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nature Genetics, 36(11), 1159–1161.PubMedCrossRef
48.
Li, Y., & Benezra, R. (1996). Identification of a human mitotic checkpoint gene: hsMAD2. Science, 274(5285), 246–248.PubMedCrossRef
49.
Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010). Genomic instability—an evolving hallmark of cancer. Nature Reviews Molecular Cell Biology, 11(3), 220–228.PubMedCrossRef
50.
Maher, C. A., & Wilson, R. K. (2012). Chromothripsis and human disease: piecing together the shattering process. Cell, 148(1–2), 29–32.PubMedCrossRef
51.
Forment, J. V., Kaidi, A., & Jackson, S. P. (2012). Chromothripsis and cancer: causes and consequences of chromosome shattering. Nature Reviews. Cancer, 12(10), 663–670.PubMedCrossRef
52.
Abdel-Rahman, W. M., Katsura, K., Rens, W., Gorman, P. A., Sheer, D., Bicknell, D., et al. (2001). Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. Proceedings of the National Academy of Sciences of the United States of America, 98(5), 2538–2543.PubMedCrossRef
53.
Muresu, R., Sini, M. C., Cossu, A., Tore, S., Baldinu, P., Manca, A., et al. (2002). Chromosomal abnormalities and microsatellite instability in sporadic endometrial cancer. European Journal of Cancer, 38(13), 1802–1809.PubMedCrossRef
54.
Geigl, J. B., Obenauf, A. C., Schwarzbraun, T., & Speicher, M. R. (2008). Defining ‘chromosomal instability’. Trends in Genetics: TIG, 24(2), 64–69.PubMedCrossRef
55.
Wan, T. S., & Ma, E. S. (2012). Molecular cytogenetics: an indispensable tool for cancer diagnosis. Chang Gung Medical Journal, 35(2), 96–110.PubMed
56.
Beheshti, B., Park, P. C., Sweet, J. M., Trachtenberg, J., Jewett, M. A., & Squire, J. A. (2001). Evidence of chromosomal instability in prostate cancer determined by spectral karyotyping (SKY) and interphase FISH analysis. Neoplasia, 3(1), 62–69.PubMedCrossRef
57.
Bayani, J., & Squire, J. A. (2001). Advances in the detection of chromosomal aberrations using spectral karyotyping. Clinical Genetics, 59(2), 65–73.PubMedCrossRef
58.
Ye, C. J., Stevens, J. B., Liu, G., Bremer, S. W., Jaiswal, A. S., Ye, K. J., et al. (2009). Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. Journal of Cellular Physiology, 219(2), 288–300.PubMedCrossRef
59.
Zong, C., Lu, S., Chapman, A. R., & Xie, X. S. (2012). Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science, 338(6114), 1622–1626.PubMedCrossRef
60.
Darzynkiewicz, Z., Halicka, H. D., & Zhao, H. (2010). Analysis of cellular DNA content by flow and laser scanning cytometry. Advances in Experimental Medicine and Biology, 676, 137–147.PubMedCrossRef
61.
D'Urso, V., Collodoro, A., Mattioli, E., Giordano, A., & Bagella, L. (2010). Cytometry and DNA ploidy: clinical uses and molecular perspective in gastric and lung cancer. Journal of Cellular Physiology, 222(3), 532–539.PubMed
62.
Ishkanian, A. S., Malloff, C. A., Watson, S. K., DeLeeuw, R. J., Chi, B., Coe, B. P., et al. (2004). A tiling resolution DNA microarray with complete coverage of the human genome. Nature Genetics, 36(3), 299–303.PubMedCrossRef
63.
Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., et al. (1998). High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genetics, 20(2), 207–211.PubMedCrossRef
64.
Heinrichs, S., & Look, A. T. (2007). Identification of structural aberrations in cancer by SNP array analysis. Genome Biology, 8(7), 219.PubMedCrossRef
65.
Zhao, X., Li, C., Paez, J. G., Chin, K., Janne, P. A., Chen, T. H., et al. (2004). An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Research, 64(9), 3060–3071.PubMedCrossRef
66.
Gondek, L. P., Tiu, R., Haddad, A. S., O'Keefe, C. L., Sekeres, M. A., Theil, K. S., et al. (2007). Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK, 21(9), 2058–2061.CrossRef
67.
Goel, A., Nagasaka, T., Hamelin, R., & Boland, C. R. (2010). An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PloS One, 5(2), e9393.PubMedCrossRef
68.
Janavicius, R., Matiukaite, D., Jakubauskas, A., & Griskevicius, L. (2010). Microsatellite instability detection by high-resolution melting analysis. Clinical Chemistry, 56(11), 1750–1757.PubMedCrossRef
69.
Meyerson, M., Gabriel, S., & Getz, G. (2010). Advances in understanding cancer genomes through second-generation sequencing. Nature Reviews Genetics, 11(10), 685–696.PubMedCrossRef
70.
Wheeler, D. A., Srinivasan, M., Egholm, M., Shen, Y., Chen, L., McGuire, A., et al. (2008). The complete genome of an individual by massively parallel DNA sequencing. Nature, 452(7189), 872–876.PubMedCrossRef
71.
Ng, P. C., & Kirkness, E. F. (2010). Whole genome sequencing. Methods in Molecular Biology, 628, 215–226.PubMedCrossRef
72.
Campbell, P. J., Stephens, P. J., Pleasance, E. D., O'Meara, S., Li, H., Santarius, T., et al. (2008). Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nature Genetics, 40(6), 722–729.PubMedCrossRef
73.
Chiang, D. Y., Getz, G., Jaffe, D. B., O'Kelly, M. J., Zhao, X., Carter, S. L., et al. (2009). High-resolution mapping of copy-number alterations with massively parallel sequencing. Nature Methods, 6(1), 99–103.PubMedCrossRef
74.
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 455(7216), 1069–1075.PubMedCrossRef
75.
Bell, D. (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474(7353), 609–615.CrossRef
76.
McLendon, R. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455(7216), 1061–1068.CrossRef
77.
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., et al. (2012). The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature, 486(7403), 395–399.PubMed
78.
Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee J, Jung YJ, Kim JO, Yu SB et al. (2012). The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Research, 22, 2109–2119.
79.
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A. Y., et al. (2011). The genomic complexity of primary human prostate cancer. Nature, 470(7333), 214–220.PubMedCrossRef
80.
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Angenendt, P., et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 321(5897), 1801–1806.PubMedCrossRef
81.
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjoblom, T., Leary, R. J., et al. (2007). The genomic landscapes of human breast and colorectal cancers. Science, 318(5853), 1108–1113.PubMedCrossRef
82.
Mitelman, F., Johansson, B., & Mertens, F. (2004). Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nature Genetics, 36(4), 331–334.PubMedCrossRef
83.
Vollebergh, M. A., Jonkers, J., & Linn, S. C. (2012). Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cellular and Molecular Life Sciences: CMLS, 69(2), 223–245.PubMedCrossRef
84.
Huang, Y. T., Lin, X., Liu, Y., Chirieac, L. R., McGovern, R., Wain, J., et al. (2011). Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 108(39), 16345–16350.PubMedCrossRef
85.
Massion, P. P., Zou, Y., Chen, H., Jiang, A., Coulson, P., Amos, C. I., et al. (2008). Smoking-related genomic signatures in non-small cell lung cancer. American Journal of Respiratory and Critical Care Medicine, 178(11), 1164–1172.PubMedCrossRef
86.
Thu, K. L., Vucic, E. A., Chari, R., Zhang, W., Lockwood, W. W., English, J. C., et al. (2012). Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability. PloS One, 7(3), e33003.PubMedCrossRef
87.
Bowtell, D. D. (2010). The genesis and evolution of high-grade serous ovarian cancer. Nature Reviews. Cancer, 10(11), 803–808.PubMedCrossRef
88.
Fang, M., Toher, J., Morgan, M., Davison, J., Tannenbaum, S., & Claffey, K. (2011). Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis. Cancer, 117(10), 2024–2034.PubMedCrossRef
89.
Lockwood, W. W., Wilson, I. M., Coe, B. P., Chari, R., Pikor, L. A., Thu, K. L., et al. (2012). Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PloS One, 7(5), e37775.PubMedCrossRef
90.
Wilkerson, M. D., Yin, X., Walter, V., Zhao, N., Cabanski, C. R., Hayward, M. C., et al. (2012). Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PloS One, 7(5), e36530.PubMedCrossRef
91.
Loeb, L. A. (2011). Human cancers express mutator phenotypes: origin, consequences and targeting. Nature Reviews. Cancer, 11(6), 450–457.PubMedCrossRef
Metadata
Title
The detection and implication of genome instability in cancer
Authors
Larissa Pikor
Kelsie Thu
Emily Vucic
Wan Lam
Publication date
01-12-2013
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3-4/2013
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-013-9429-5

Other articles of this Issue 3-4/2013

Cancer and Metastasis Reviews 3-4/2013 Go to the issue

NON-THEMATIC REVIEW

The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation

NON-THEMATIC REVIEW

Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review

OriginalPaper

Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells

NON-THEMATIC REVIEW

Role of the host stroma in cancer and its therapeutic significance

NON-THEMATIC REVIEW

Tumor type-specific and skin region-selective metastasis of human cancers: another example of the “seed and soil” hypothesis

NON-THEMATIC REVIEW

The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits